CN1303937A - Novel polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide - Google Patents
Novel polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide Download PDFInfo
- Publication number
- CN1303937A CN1303937A CN 99119862 CN99119862A CN1303937A CN 1303937 A CN1303937 A CN 1303937A CN 99119862 CN99119862 CN 99119862 CN 99119862 A CN99119862 A CN 99119862A CN 1303937 A CN1303937 A CN 1303937A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- polynucleotide
- anion transport
- human tissue
- tissue anion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The present invention discloses a novel polypeptide-human tissue anion rotation polypeptide 41, polynucleotide coding said polypeptide and its method for producing said polypeptide by using DNA recombination technology. Said invention also discloses the method for curing several diseases, such as malignant tumor, blood disease, HIV infection, immunological disease and various inflammations by using said polypeptide. Said invention also discloses an antagonist resisting said polypeptide and its therapeutic effect, and also discloses the application of polynucleotide for coding this novel human tissue anion rotation polypeptide 41.
Description
The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide-human tissue anion transport polypeptide 41, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.
Liver cell can be by liver substrate outside cell from a large amount of different lipotropy tissue anion such as multiple bile negatively charged ion and the steroid mixtures of sinus hepaticus shape blood tubule picked-up; sodium ion dependency and the dependent movement system of non-sodium ion are positioned on the cytoplasmic membrane zone, the liver substrate outside; preferentially absorbed by sodium ion-taurocholate co-transport polypeptide (NTCP) with taurine (or glycine) bonded cholic acid by liver cell; this all finds (Hagenbuch B et al., 1991) in mouse and human liver cell.On the other hand, liver cell is to carry out by the dependent carrier of non-sodium ion to the picked-up of the tissue anion of non-cholic acid bonding state uniquely, these carriers may comprise bile transport kinases (37KD), bromosulfalein and bilirubin conjugated protein (55KD), a kind of special organization negatively charged ion conjugated protein (55KD) (Tiribelli C., 1990; Berk PD etal., 1987; Wolkoff AW et al.; 1993); mouse of having been cloned and human liver tissue anion transport polypeptide 74 also carry out the transhipment (Jacquemin E et al., 1994) of the dependent tissue anion of non-sodium ion such as bromsulf alein salt, cholate, taurocholate, GC, deoxidation taurocholate etc. in addition.
Human liver tissue anion transport polypeptide (OATP) 74 genes are made up of 2737 Nucleotide, the poly A tail that contains 16 base pairs, its initiation site is at the 54th Nucleotide place, its open reading frame sequence extends beyond 2010 Nucleotide, encodes one to contain the albumen that contains 8 potential N-glycosylation sites that 670 amino acid molecular amounts are 74KD.The sequence of human liver tissue anion transport polypeptide 74 prompting albumen contains 10-12 and strides diaphragm area, 8 N-glycosylation sites, and 4 N-glycosylation sites wherein are positioned on the big hydrophilic Lu puff of membrane spaning domain 9-12 (Kullak-Ublick et al.1995).Human liver tissue anion transport polypeptide 74 is very close with rat tissue anion transport polypeptide 74, both have 67% homology, 82% similarity, rat tissue anion transport polypeptide 74 may contain 10 membrane spaning domains, 4 N-glycosylation site (JacqueminE et al., 1994), both all belong to tissue anion transport polypeptide gene family (Kullak-Ublicket al.1995) probably.
With people liver OATP complementary RNA is probe, and the Northern hybridization analysis shows that the intersection from the mRNA of people's liver, brain, lung, kidney, testis activates.Studies show that further high-intensity hybridization signal occurs in the full mRNA of human brain, liver mRNA, kidney mRNA, and some Notes of Key Data people OATP occur in a variety of forms in many tissues, mainly show as the size of molecular weight.People OATP plays an important role on the total tissue anion transport of human body.People liver OATP existence of multiple tissue outside liver has hinted its vital role (Kullak-Ublick et al., 1995) in the negatively charged ion transepithelial transportation of tissue generally.
People's of the present invention tissue anion transport polypeptide 41 genes and people's tissue anion transport polypeptide 74 genes have 46% homology on protein level, with tissue anion transport polypeptide 74 genes of mouse 45% homology (homologous protein U21943) is arranged on protein level, its structural domain is similar in appearance to the characteristic structural domain of tissue anion transport polypeptide gene family--and-10-12 membrane spaning domain, a 4-8 N-glycosylation site, several N-glycosylation sites wherein are positioned on the big hydrophilic Lu puff of membrane spaning domain.Based on above each point, so think that new gene of the present invention is the gene of a coding human tissue anion transport polypeptide gene family, called after human tissue anion transport polypeptide 41.And infer that with this its structural domain is similar to tissue anion transport polypeptide gene family structure territory, have similar biological function.
The polynucleotide of coding human tissue anion transport polypeptide 41, and coded human tissue anion transport polypeptide 41 be found to be the differentiation of research cell under normal and pathological conditions, the physiological and biochemical procedure of propagation provides a kind of method, also comprises that with the disease that the disorder of cytodifferentiation propagation causes cancer provides a kind of new way for diagnosis, treatment.
An object of the present invention is to provide isolating new polypeptide-human tissue anion transport polypeptide 41 with and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of this polypeptide of coding.
Another object of the present invention provides the recombinant vectors of the polynucleotide that contain coding human tissue anion transport polypeptide 41.
Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain coding human tissue anion transport polypeptide 41.
Another object of the present invention provides the method for producing human tissue anion transport polypeptide 41.
Another object of the present invention provides the antibody at polypeptide-human tissue anion transport polypeptide 41 of the present invention.
Another object of the present invention has provided simulated compound, antagonist, agonist, the inhibitor at polypeptide-human tissue anion transport polypeptide 41 of the present invention.
Another object of the present invention provides the method for the unusual relevant disease of diagnoses and treatment and human tissue anion transport polypeptide 41.
In a first aspect of the present invention, novel isolated human tissue anion transport polypeptide 41 is provided, this polypeptide is the people source, and it comprises: have the polypeptide of SEQ ID NO:2 aminoacid sequence or its conservative property variation polypeptide or its active fragments or its reactive derivative, analogue.Preferably, this polypeptide is the polypeptide with SEQ ID NO:2 aminoacid sequence.
In a second aspect of the present invention, the polynucleotide of isolating these polypeptide of coding are provided, these polynucleotide comprise a nucleotide sequence, and this nucleotide sequence is shown at least 70% homogeny with a kind of nucleotides sequence that is selected from down group: (a) polynucleotide of the above-mentioned human tissue anion transport polypeptide 41 of coding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, this polynucleotide encoding has the polypeptide of aminoacid sequence shown in the SEQ ID NO:2.More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 75-1208 position among the SEQ ID NO:1; (b) has the sequence of 1-2061 position among the SEQ ID NO:1.
In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.
As used herein, " isolating human tissue anion transport polypeptide 41 " is meant that human tissue anion transport polypeptide 41 is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying human tissue anion transport polypeptide 41 of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of human tissue anion transport polypeptide 41 polypeptide can be used amino acid sequence analysis.
The invention provides a kind of new polypeptide-human tissue anion transport polypeptide 41, it is made up of the aminoacid sequence shown in the SEQID NO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises fragment, derivative and the analogue of human tissue anion transport polypeptide 41.As used herein, term " fragment ", " derivative " and " analogue " are meant biological function or the active polypeptide that keeps human tissue anion transport polypeptide of the present invention 41 identical basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) is a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.
The invention provides isolating nucleic acid (polynucleotide), substantially the polynucleotide that have a polypeptide of SEQ ID NO:2 aminoacid sequence by coding are formed.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 2061 bases, and its open reading frame (75---1208) 377 amino acid of having encoded.Find relatively that according to amino acid sequence homologous the tissue anion transport polypeptide of this polypeptide and mouse has 45% homology, deducibility goes out the similar 26S Proteasome Structure and Function of tissue anion transport polypeptide that this human tissue anion transport polypeptide 41 has mouse.
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has protein or the polypeptide of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.
The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.
The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of coding human tissue anion transport polypeptide 41.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
The special polynucleotide sequence of coding human tissue anion transport polypeptide 41 of the present invention can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.
Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.
In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.
Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) level of the transcript of human tissue anion transport polypeptide 41 is measured in the appearance of marker gene function or forfeiture (3); (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.
In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.
In (4) kind method, detect the protein product of human tissue anion transport polypeptide 41 genetic expressions and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.
Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.
The present invention also relates to comprise the carrier of polynucleotide of the present invention, and with carrier of the present invention or directly with the host cell of human tissue anion transport polypeptide 41 encoding sequences, and the method that produces polypeptide of the present invention through recombinant technology through the genetically engineered generation.
Among the present invention, the polynucleotide sequence of coding human tissue anion transport polypeptide 41 can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); (Lee and Nathans, J Bio Chem.263:3521 is l988) with at the carrier that derives from baculovirus of expressed in insect cells for the pMSXND expression vector of expressing in mammalian cell.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.
Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains coding human tissue anion transport polypeptide 41 and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, aLaboratory Manual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The P of lambda particles phage
LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.
Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.
Among the present invention, the polynucleotide of coding human tissue anion transport polypeptide 41 or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.
Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results
2Method is handled, and used step is well-known in this area.Alternative is to use MgCl
2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.
By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce human tissue anion transport polypeptide 41 (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:
(1). with the polynucleotide (or varient) of coding of the present invention people human tissue anion transport polypeptide 41, or with the recombinant expression vector that contains these polynucleotide proper host cell that transforms or transduce;
(2). in suitable medium, cultivate host cell;
(3). separation, protein purification from substratum or cell.
In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.
People OATP plays an important role at the total tissue anion transport of human body.These tissue anions comprise the dependent bromsulf alein salt of non-sodium ion, combine with bile or uncombined cholate, taurate, glycinate, deoxidation taurate or the like.The abnormal expression of human tissue anion transport polypeptide 41 of the present invention will produce especially metabolic disease of various diseases.These metabolic diseases include but not limited to: (1) amino acid metabolism defective disease: as pku, tyrosine metabolic deficiency disease such as the high junket base acidaemia of newborn infant's one property crossed, subacute and the chronic tyrosinemia of acute tyrosine, albinism, the sulfur-containing amino acid metabolic defect, tryptophane metabolic defect such as heredity pellagra, look amino mass formed by blood stasis, the branched chain amino acid metabolic defect, glycine metabolic defect such as glycinemia, hypersarcosinemia, the D-glyceric acidemia, front three aminuria disease, glycinuria and Glucoglycinuria disease, primary oxalic acid disease and oxaluria, proline(Pro) and oxyproline metabolic defect, glutamic acid metabolism defective disease, the metabolic defect of ornithine cycle, the Histidine metabolic defect, Methionin metabolic defect, and other amino acid metabolism defective disease.(2) mucopolysaccharidosis and other marginality diseases.(3) purine and pyrimidine metabolic defective disease.(4) lipid metabolism is unusual.(5) carbohydrate metabolism defective disease: digest and assimilate defective, monose metabolic defect, Glycogen Metabolism disease as congenital carbohydrate.
People OATP has high-intensity expression at people's liver, brain, lung, kidney, testis, and some Notes of Key Data people OATP appearance in a variety of forms in many tissues, mainly shows as the size of molecular weight.People liver OATP existence of multiple tissue outside liver has hinted its vital role in the negatively charged ion transepithelial transportation of tissue generally.The abnormal expression of human tissue anion transport polypeptide 41 of the present invention will produce the especially various diseases at positions such as liver, brain, lung, kidney, testis of various diseases.These diseases include but not limited to: grow metabolism disorder disease such as cholehepatocirrhosis (cholestasis liver cirrhosis, the cholehepatocirrhosis of bile duct inflammatory, primary biliary cirrhosis), portal cirrhosis, postnecrotic cirrhosis, stasis cirrhosis, the pigment liver cirrhosis, congenital hydrocephalus, cerebral edema, pulmonary alveolar proteinosis, respiratory distress syndrome, pneumoconiosis disease, the renal glomerular disease that metabolic disturbance causes such as the injury of the kidney of amyloidosis, the renal toxicity acute tubular necrosis, hypertonicity tubulopathy, congenital deformity of testis; Various inflammation such as viral hepatitis, viral and bacterial encephalitis, various pneumonia, various ephritis, testis inflammation; Various tumours such as primary hepatocarcinoma, hepatoblastoma, primary carcinoma of gallbladder, astrocytoma, ependymoma, medulloblastoma, meningioma, glioma, lung cancer, renal cortex tubule adenoma, acidophile adenoma, JGCT, polycystic Kidney knurl, spermocytoma, ball Leydig's cell tumor, renal cell carcinoma, sarcoma of kidney sample cancer, nipple sample renal cell carcinoma, the nephroblastoma; Some heredopathia, hemopathy and disease of immune system.
The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of (antagonist) human tissue anion transport polypeptide 41.Agonist improves human tissue anion transport polypeptide 41 biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can in the presence of medicine, the film preparation of mammalian cell or expressing human tissue anion transport polypeptide 41 be cultivated with the human tissue anion transport polypeptide 41 of mark.Measure the medicine raising then or check this interactional ability.
The antagonist of human tissue anion transport polypeptide 41 comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of human tissue anion transport polypeptide 41 can combine and eliminate its function with human tissue anion transport polypeptide 41, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.
In screening during as the compound of antagonist, human tissue anion transport polypeptide 41 can be added in the bioanalysis mensuration, interactional influence between human tissue anion transport polypeptide 41 and its acceptor be determined whether compound is antagonist by measuring compound.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with human tissue anion transport polypeptide 41 bonded peptide molecules obtains.During screening, generally tackle human tissue anion transport polypeptide 41 molecules and carry out mark.
The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at human tissue anion transport polypeptide 41 antigenic determinants.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.
The method of the available human tissue anion transport polypeptide 41 direct injection immune animals of the production of polyclonal antibody (as rabbit, mouse, rat etc.) obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of preparation human tissue anion transport polypeptide 41 includes but not limited to hybridoma technology (Kohler and Milstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of anti-human tissue anion transport polypeptide 41.
The antibody of anti-human tissue anion transport polypeptide 41 can be used in the immunohistochemistry technology, detects the human tissue anion transport polypeptide 41 in the biopsy specimen.
With the also available labelled with radioisotope of human tissue anion transport polypeptide 41 bonded monoclonal antibodies, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.
Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of human tissue anion transport polypeptide 41 high-affinities can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing human tissue anion transport polypeptide 41 positive cells.
The disease that antibody among the present invention can be used for treating or prevention and human tissue anion transport polypeptide 41 are relevant.The antibody that gives suitable dosage can stimulate or block the generation or the activity of human tissue anion transport polypeptide 41.
The invention still further relates to the diagnostic testing process of quantitative and detection and localization human tissue anion transport polypeptide 41 levels.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.Human tissue anion transport polypeptide 41 levels that detected in the test can be with laying down a definition the importance of human tissue anion transport polypeptide 41 in various diseases and be used to the disease of diagnosing human tissue anion transport polypeptide 41 to work.
Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.
The polynucleotide of coding human tissue anion transport polypeptide 41 also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of human tissue anion transport polypeptide 41 or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for the human tissue anion transport polypeptide 41 of expressing variation, to suppress endogenic human tissue anion transport polypeptide 41 activity.For example, a kind of human tissue anion transport polypeptide 41 of variation can be the human tissue anion transport polypeptide 41 that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of 41 expression of human tissue anion transport polypeptide or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the polynucleotide of coding human tissue anion transport polypeptide 41 are transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of coding human tissue anion transport polypeptide 41 is found in existing document (Sambrook, et al.).The polynucleotide of reorganization coding human tissue anion transport polypeptide 41 can be packaged in the liposome and be transferred in the cell in addition.
Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.
Suppress the oligonucleotide (comprising sense-rna and DNA) of human tissue anion transport polypeptide 41mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.
The polynucleotide of coding human tissue anion transport polypeptide 41 can be used for the diagnosis with the relative disease of human tissue anion transport polypeptide 41.The unconventionality expression of the expression that the polynucleotide of coding human tissue anion transport polypeptide 41 can be used for detecting human tissue anion transport polypeptide 41 human tissue anion transport polypeptide 41 whether or under morbid state.As the dna sequence dna of the human tissue anion transport polypeptide 41 of encoding can be used for biopsy specimen is hybridized to judge the expression situation of human tissue anion transport polypeptide 41.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect human tissue anion transport polypeptide 41 with human tissue anion transport polypeptide 41 special primers.
The sudden change that detects human tissue anion transport polypeptide 41 genes also can be used for diagnosing the relevant disease of human tissue anion transport polypeptide 41.The form of human tissue anion transport polypeptide 41 sudden change comprises that the point mutation compared with normal wild type human tissue anion transport polypeptide 41 dna sequence dnas, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.
In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).
The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).
In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.
Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.
Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.
The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.
Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Human tissue anion transport polypeptide 41 comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to patient's human tissue anion transport polypeptide 41 will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.
Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.
Fig. 1 is the tissue anion transport amino acid sequence of polypeptide homology comparison diagram of inventor's tissue anion transport polypeptide 41 and mouse.The top sequence is a human tissue anion transport polypeptide 41, and the below sequence is the tissue anion transport polypeptide of mouse.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".
Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating human tissue anion transport polypeptide 41.41kDa is proteinic molecular weight.The arrow indication is isolated protein band.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.Embodiment 1: the clone of human tissue anion transport polypeptide 41
Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).Then fixed cDNA sequence and existing public dna sequence data storehouse (Genebank) are compared, found that the cDNA sequence of one of them clone 0157b05 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 0157b05 clone is 2061bp (shown in Seq ID NO:1), from 75bp to 1208bp the open reading frame (ORF) of a 1134bp, the new protein (shown in Seq ID NO:2) of encoding arranged.We are with this clone's called after pBS-0157b05, encoded protein matter called after human tissue anion transport polypeptide 41.
Embodiment 2:cDNA clone's homology retrieval
With the sequence and the encoded protein sequence thereof of human tissue anion transport polypeptide 41 of the present invention, with Blast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene the highest with human tissue anion transport polypeptide 41 homologys of the present invention is the tissue anion transport polypeptide of a kind of known mouse, and its encoded protein number is A49580 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 45%; Similarity is 64%.Embodiment 3: with the gene of RT-PCR method clones coding human tissue anion transport polypeptide 41
Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:
Primer1:5’-CCTCTGAGAAATCCAAGTTTATTATAG-3’(SEQ?ID?NO:3)
Primer2:5’-GTTGTAACACCTACATTTATTGTAGAC-3’(SEQ?ID?NO:4)
Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;
Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.
The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/L Tris-Cl, (pH8.5), 1.5mmol/L MgCl
2, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-206Ibp shown in the SEQ ID NO:1 are identical.Embodiment 4:Northern blotting analyst tissue anion transport polypeptide 41 expression of gene:
Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α-
32P dATP prepares by random priming
32The dna probe of P-mark.Used dna probe is human tissue anion transport polypeptide 41 coding region sequences (75bp to 1208bp) of pcr amplification shown in Figure 1.Probe (about 2 * 10 with the 32P-mark
6Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH
2PO
4(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.Embodiment 5: vivoexpression, separation and the purifying of recombinant human tissue anion transport polypeptide 41
According to SEQ ID NO:1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:
Primer3:5’-CCCCCATGGATGGAAATGGCAAGAGATTTTCTTCC-3’(Seq?ID?No:5)
Primer4:5’-CCCGGATCCCCAAGTTGAGTTTCCTTGCCTGGCC-3’?(Seq?ID?No:6)
5 ' end of these two sections primers contains Nco I and BamH I restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, Nco I and BamH I restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-0157b05 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-0157b05 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with Nco I and BamH I, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-0157b05) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) DlySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-0157b05) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the target protein human tissue anion transport polypeptide 41 of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 36kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.Embodiment 6 anti-human tissue anion transport polypeptide 41 production of antibodies
Synthesize following human tissue anion transport polypeptide 41 specific polypeptide with Peptide synthesizer (PE company product):
NH
2-Met-Glu-Met-Ala-Arg-Asp-Phe-Leu-Pro-Ser-Leu-Lys-Asn-Leu-Phe-COOH
(SEQ?ID?NO:7)。Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with human tissue anion transport polypeptide 41 specifically.
Sequence table
(1) general information:
(ⅱ) denomination of invention: human tissue anion transport polypeptide 41 and encoding sequence thereof
(ⅲ) sequence number: 7
(2) information of SEQ ID NO:1:
(ⅰ) sequence signature:
(A) length: 2061bp
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity
(ⅱ) molecule type: cDNA
( ⅹⅰ ) ：SEQ ID NO:1： 1 CCTCTGAGAAATCCAAGTTTATTATAGATGATCACACAGACTACCAAACACCCCAGGGAG 61 AAAATGCAAAAATAATGGAAATGGCAAGAGATTTTCTTCCATCACTGAAGAATCTTTTTG121 GAAACCCAGTATACTTCCTATATTTATGTACAAGCACTGTTCAGTTCAATTCTCTGTTCG181 GCATGGTGACGTACAAACCAAAGTACATTGAGCAGCAGTATGGACAGTCATCCTCCAGGG241 CCAACTTTGTGATCGGGCTCATCAACATTCCAGCAGTGGCCCTTGGGATATTCTCTGGGG301 GGATAGTTATGAAAAAATTCAGAATCAGTGTGTGTGGAGCTGCGAAACTCTACTTGGGAT361 CATCTGTCTTTGGTTACCTCCTATTTCTTTCCCTGTTTGCACTGGGCTGTGAAAATTCTG421 ATGTGGCAGGACTAACTGTCTCCTACCAAGGAACCAAACCTGTCTCTTATCATGAACGAG481 CTCTCTTTTCAGATTGCAACTCAAGATGCAAATGTTCAGAGACAAAATGGGAACCCATGT541 GCGGTGAAAATGGAATCACATATGTATCAGCTTGTCTTGCTGGTTGTCAAACCTCCAACA601 GGAGTGGAAAAAATATTATATTTTACAACTGCACTTGTGTGGGAATTGCAGCTTCTAAAT661 CCGGAAATTCCTCAGGCATAGTGGGAAGATGTCAGAAAGACAATGGATGTCCCCAAATGT721 TTCTGTATTTCCTTGTAATTTCAGTCACCACATCCTATACTTTATCCCTAGGTGGCATAC781 CTGGATACATATTACTTCTGAGGTGCATTAAGCCACAGCTTAAGTCTTTTGCCTTGGGTA841 TCTACACATTAGCAATAAGAGTTCTTGCAGGAATCCCAGCTCCAGTGTATTTTGGAGTTT901 TGATTGATACTTCATGCCTCAAATGGGGATTTAAAAGATGTGGAAGTAGAGGATCATGCA 961 GATTATATGATTCAAATGTCTTCAGACATATATATTTGGGACTAACTGTGATACTGGGCA1021 CAGTGTCAATTCTCCTAAGCATTGCAGTACTTTTCATTTTAAAGAAAAATTATGTTTCAA1081 AACACAGAAGTTTTATAACCAAGAGAGAAAGAACAATGGTGTCTACAAGATTCCAAAAGG1141 AAAATTACACTACAAGTGATCATCTGCTACAACCCAACTACTGGCCAGGCAAGGAAACTC1201 AACTTTAGAAACATGATGACTGGAAGTCATGTCTTCTAATTGGTTGACATTTTGCAAACA1261 AATAAATTGTAATCAAAAGAGCTCTAAATTTGTAATTTCTTTCTCCTTTCAAAAAATGCC1321 TACTTTGTTTTGGTCCTAGGCATTAGGTAATATAACTGATAATATACTGAAATATATAAT1381 GGAAGATGCAGATGATAAAACTAATTTTGAACTTTTTAATTTATATAAATTATTTTATAT1441 CATTTACTTATTTCACTTTATTTTGCTTTGTGCTCATTGATATATATTAGCTGTACTCCT1501 AGAAGAACAATTGTCTCTATTGTCACACATGGTTATATTTAAAGTAATTTCTGAACTGTG1561 TAATGTGTCTAGAGTAAGCAAATACTGCTAACAATTAACTCATACCTTGGGTTCCTTCAA1621 GTATTACTCCTATAGTATTTTCTCCCATAGCTGTCTTCATCTGTGTATTTTAATAATGAT1681 CTTAGGATGGAGCAGAACATGGAGAGGAAGATTTCATTTTAAGCTCCTCCTTTTCCTTGA1741 AATACAATAATTTATATAGAAATGTGTAGCAGCAAATTATATTGGGGATTAGAATTTTGA1801 ATTAATAGCTCTCCTACTATTAATTTACATGTGCTTTTTGTGTGGCGCTATAAGTGACTA1861 TGGTTGTAAAGTAATAAAATTGATGTTAACATGCCCAATTATTGTTCTTTTATGAATTCA1921 ATGAATTTAAAACTATTGTTAAATATAATACTGCCCCACTTTAATATATGTAAGCAACTT1981 CCTACTTATACACGACGTGTTCCTAAAACATGTTTGAAAGGTGAATTTCTGAAAGTCTAC2041 AATAAATGTAGGTGTTACAAC
(3) information of SEQ ID NO:2:
(ⅰ) sequence signature:
(A) length: 377 amino acid
(B) type: amino acid
(D) topological framework: linearity
(ⅱ) molecule type: polypeptide
( ⅹⅰ ) ：SEQ ID NO:2： 1 Met Glu Met Ala Arg Asp Phe Leu Pro Ser Leu Lys Asn Leu Phe16 Gly Asn Pro Val Tyr Phe Leu Tyr Leu Cys Thr Ser Thr Val Gln31 Phe Asn Ser Leu Phe Gly Met Val Thr Tyr Lys Pro Lys Tyr Ile46 Glu Gln Gln Tyr Gly Gln Ser Ser Ser Arg Ala Asn Phe Val Ile61 Gly Leu Ile Asn Ile Pro Ala Val Ala Leu Gly Ile Phe Ser Gly 76 Gly Ile Val Met Lys Lys Phe Arg Ile Ser Val Cys Gly Ala Ala 91 Lys Leu Tyr Leu Gly Ser Ser Val Phe Gly Tyr Leu Leu Phe Leu106 Ser Leu Phe Ala Leu Gly Cys Glu Asn Ser Asp Val Ala Gly Leu121 Thr Val Ser Tyr Gln Gly Thr Lys Pro Val Ser Tyr His Glu Arg136 Ala Leu Phe Ser Asp Cys Asn Ser Arg Cys Lys Cys Ser Glu Thr151 Lys Trp Glu Pro Met Cys Gly Glu Asn Gly Ile Thr Tyr Val Ser166 Ala Cys Leu Ala Gly Cys Gln Thr Ser Asn Arg Ser Gly Lys Asn181 Ile Ile Phe Tyr Asn Cys Thr Cys Val Gly Ile Ala Ala Ser Lys196 Ser Gly Asn Ser Ser Gly Ile Val Gly Arg Cys Gln Lys Asp Asn211 Gly Cys Pro Gln Met Phe Leu Tyr Phe Leu Val Ile Ser Val Thr226 Thr Ser Tyr Thr Leu Ser Leu Gly Gly Ile Pro Gly Tyr Ile Leu241 Leu Leu Arg Cys Ile Lys Pro Gln Leu Lys Ser Phe Ala Leu Gly256 Ile Tyr Thr Leu Ala Ile Arg Val Leu Ala Gly Ile Pro Ala Pro271 Val Tyr Phe Gly Val Leu Ile Asp Thr Ser Cys Leu Lys Trp Gly286 Phe Lys Arg Cys Gly Ser Arg Gly Ser Cys Arg Leu Tyr Asp Ser301 Asn Val Phe Arg His Ile Tyr Leu Gly Leu Thr Val Ile Leu Gly316 Thr Val Ser Ile Leu Leu Ser Ile Ala Val Leu Phe Ile Leu Lys331 Lys Asn Tyr Val Ser Lys His Arg Ser Phe Ile Thr Lys Arg Glu346 Arg Thr Met Val Ser Thr Arg Phe Gln Lys Glu Asn Tyr Thr Thr361 Ser Asp His Leu Leu Gln Pro Asn Tyr Trp Pro Gly Lys Glu Thr376 Gln Leu
(4) information of SEQ ID NO:3
(ⅰ) sequence signature
(A) length: 27 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ⅱ) molecule type: oligonucleotide
(ⅹ ⅰ) sequence description: SEQ ID NO:3:CCTCTGAGAAATCCAAGTTTATTATAG 27
(5) information of SEQ ID NO:4
(ⅰ) sequence signature
(A) length: 27 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ⅱ) molecule type: oligonucleotide
(ⅹ ⅰ) sequence description: SEQ ID NO:4:GTTGTAACACCTACATTTATTGTAGAC 27
(6) information of SEQ ID NO:5
(ⅰ) sequence signature
(A) length: 35 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ⅱ) molecule type: oligonucleotide
(ⅹ ⅰ) sequence description: SEQ ID NO:5:CCCCCATGGATGGAAATGGCAAGAGATTTTCTTCC 35
(7) information of SEQ ID NO:6
(ⅰ) sequence signature
(A) length: 34 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ⅱ) molecule type: oligonucleotide
(ⅹ ⅰ) sequence description: SEQ ID NO:6:CCCGGATCCCCAAGTTGAGTTTCCTTGCCTGGCC 34
(8) information of SEQ ID NO:7:
(ⅰ) sequence signature:
(A) length: 15 amino acid
(B) type: amino acid
(D) topological framework: linearity
(ⅱ) molecule type: polypeptide
(ⅹ ⅰ) sequence description: SEQ ID NO:7:Met-Glu-Met-Ala-Arg-Asp-Phe-Leu-Pro-Ser-Leu-Lys-Asn-Leu-Phe 15
Claims (18)
1, a kind of isolated polypeptide-human tissue anion transport polypeptide 41 is characterized in that it includes: the polypeptide of the aminoacid sequence shown in the SEQ IDNO:2 or the active fragments of its polypeptide, analogue or derivative.
2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in the SEQ ID NO:2.
3, polypeptide as claimed in claim 2 is characterized in that it comprises the polypeptide with the aminoacid sequence shown in the SEQ ID NO:2.
4, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:
(a) coding has the polynucleotide of the polypeptide of aminoacid sequence shown in the SEQ ID NO:2 or its fragment, analogue, derivative;
(b) with polynucleotide (a) complementary polynucleotide; Or
(c) with (a) or the polynucleotide of at least 70% homogeny (b) are arranged.
5, polynucleotide as claimed in claim 4 is characterized in that described polynucleotide comprise the polynucleotide that coding has aminoacid sequence shown in the SEQID NO:2.
6, polynucleotide as claimed in claim 4, the sequence that it is characterized in that described polynucleotide include the sequence of 1-2061 position among the sequence of 75-1208 position among the SEQ IDNO:1 or the SEQ ID NO:1.
7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.
8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:
(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or
(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.
9, a kind of preparation method with human tissue anion transport polypeptide 41 active polypeptide is characterized in that described method comprises:
(a) under expressing human tissue anion transport polypeptide 41 conditions, cultivate the described through engineering approaches host cell of claim 8;
(b) from culture, isolate and have human tissue anion transport polypeptide 41 active polypeptide.
10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with human tissue anion transport polypeptide 41 specificity bonded antibody.
11, the compound of an analoglike or adjusting polypeptide active or expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses human tissue anion transport polypeptide 41.
12, compound as claimed in claim 11 is characterized in that it is the polynucleotide sequence shown in the SEQ ID NO:1 or its segmental antisense sequences.
13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used for mediator's tissue anion transport polypeptide 41 in vivo, the method for external activity.
14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.
15, as the application of polypeptide as described in the arbitrary claim among the claim 1-3, it is characterized in that it is applied to screen the stand-in of human tissue anion transport polypeptide 41, agonist, antagonist or inhibitor; Perhaps be used for the peptide finger print identification.
16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.
17,, it is characterized in that forming pharmaceutical composition with safe and effective dosage and pharmaceutically acceptable carrier as the relevant unusually disease of diagnosis or treatment and human tissue anion transport polypeptide 41 with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.
18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11, it is characterized in that being used for the treatment of as malignant tumour with described polypeptide, polynucleotide or compound, hemopathy, the medicine of HIV infection and immunological disease and all kinds of inflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99119862 CN1303937A (en) | 1999-10-27 | 1999-10-27 | Novel polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99119862 CN1303937A (en) | 1999-10-27 | 1999-10-27 | Novel polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1303937A true CN1303937A (en) | 2001-07-18 |
Family
ID=5281153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99119862 Pending CN1303937A (en) | 1999-10-27 | 1999-10-27 | Novel polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1303937A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003106708A1 (en) * | 2002-06-13 | 2003-12-24 | Astrazeneca Ab | Methods for the detection of polymorphisms in the human oatpf gene |
-
1999
- 1999-10-27 CN CN 99119862 patent/CN1303937A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003106708A1 (en) * | 2002-06-13 | 2003-12-24 | Astrazeneca Ab | Methods for the detection of polymorphisms in the human oatpf gene |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1302868A (en) | Polypeptide-human F1F0 ATP synthetase subunit 15 and polynucleotide for coding it | |
| CN1303937A (en) | Novel polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide | |
| CN1292420A (en) | New human NADH oxido-reductase composite I subunit and its code sequence | |
| CN1296013A (en) | Novel human membrane granulosa protein and coding sequence | |
| CN1303930A (en) | Novel polypeptide-zinc finger protein 57 and polynucleotide coding said polypeptide | |
| CN1302877A (en) | Polypeptide-human nuclein II precursor protein 25 and polynucleotide for coding it | |
| CN1303933A (en) | Novel polypeptide-human muscle BOP protein 41 and polynucleotide coding said polypeptide | |
| CN1293204A (en) | Polypeptide-human bromo-functional protein 72 and polynucleotide for coding this polypeptide | |
| CN1302879A (en) | Polypeptide-human F-actin binding factor 75 and polynucleotide for coding it | |
| CN1470524A (en) | Polypeptide-human transcriptional elongation factor IIS51 and polynucleotide encoding this polypeptide | |
| CN1477120A (en) | A polypeptide-human tissue anion transport polypeptide 41 and polynucleotide coding said polypeptide | |
| CN1303945A (en) | Novel polypeptide-serine/threonine kinase 39 and polynucleotide coding said polypeptide | |
| CN1302881A (en) | Polypeptide-human beta-galactoside binding protein and polynucleotide for coding it | |
| CN1303944A (en) | Novel polypeptide-threonine synthetase 71 and polynucleotide coding said polypeptide | |
| CN1303926A (en) | Novel polypeptide-NADH-cytochrome B5 reductase 33 and polynucleotide coding said polypeptide | |
| CN1302815A (en) | Polypeptide-human COP9 compound subunit 30 and polynucleotide for coding it | |
| CN1303929A (en) | Novel polypeptide-robosomal protein 18 and polynucleotide coding said polypeptide | |
| CN1292385A (en) | New polypeptide-human DNA-PK interaction protein 75 and polynucleotide coding this polypeptide | |
| CN1302886A (en) | Polypeptide-human cell wither correlated protein 12 and polynucleotide for coding it | |
| CN1302817A (en) | Polypeptide-human S4 ribosomal protein 20 and polynucleotide for coding it | |
| CN1303863A (en) | Novel polypeptide-human transcriptional elongation factor IIS51 and polynucleotide for coding this polypeptide | |
| CN1303934A (en) | Novel polypeptide-human Ra1BPI related protein 82 and polynucleotide coding said polypeptide | |
| CN1303865A (en) | Novel polypeptide-human vasicentric protein 69 and polynucleotide for coding said polypeptide | |
| CN1302871A (en) | Polypeptide-human vacuolus proton-adenosine triphosphatase C subunit 42 and polynucleotide for coding it | |
| CN1303943A (en) | Novel polypeptide-CoA carboxylase 41 and polynucleotide coding said polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |